{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:05:46Z","timestamp":1792872346529,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/leu.2012.39","type":"journal-article","created":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T07:39:57Z","timestamp":1329291597000},"page":"1630-1637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL"],"prefix":"10.1038","volume":"26","author":[{"given":"M","family":"Leiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Soilihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Pallavicini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Mercurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Dal Zuffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Minucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"de Th\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"BFleu201239_CR1","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769\u2013784.","journal-title":"Nat Rev Drug Discov"},{"key":"BFleu201239_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"BFleu201239_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm1160","volume":"11","author":"A Insinga","year":"2005","unstructured":"Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71\u201376.","journal-title":"Nat Med"},{"key":"BFleu201239_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nm1161","volume":"11","author":"A Nebbioso","year":"2005","unstructured":"Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77\u201384.","journal-title":"Nat Med"},{"key":"BFleu201239_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ccr.2010.01.012","volume":"17","author":"JH Mikesch","year":"2010","unstructured":"Mikesch JH, Gronemeyer H, So CW . Discovery of novel transcriptional and epigenetic targets in APL by global ChIP analyses: Emerging opportunity and challenge. Cancer Cell 2010; 17: 112\u2013114.","journal-title":"Cancer Cell"},{"key":"BFleu201239_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/35895","volume":"391","author":"RJ Lin","year":"1998","unstructured":"Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, Evans RM . Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811\u2013814.","journal-title":"Nature"},{"key":"BFleu201239_CR7","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/35901","volume":"391","author":"F Grignani","year":"1998","unstructured":"Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815\u2013818.","journal-title":"Nature"},{"key":"BFleu201239_CR8","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood.V93.10.3167.410k44_3167_3215","volume":"93","author":"A Melnick","year":"1999","unstructured":"Melnick A, Licht JD . Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167\u20133215.","journal-title":"Blood"},{"key":"BFleu201239_CR9","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z . Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505\u20132515.","journal-title":"Blood"},{"key":"BFleu201239_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H de The","year":"2010","unstructured":"de The H, Chen Z . Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10: 775\u2013783.","journal-title":"Nat Rev Cancer"},{"key":"BFleu201239_CR11","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","volume":"114","author":"MS Tallman","year":"2009","unstructured":"Tallman MS, Altman JK . How I treat acute promyelocytic leukemia. Blood 2009; 114: 5126\u20135135.","journal-title":"Blood"},{"key":"BFleu201239_CR12","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1038\/sj.onc.1209216","volume":"25","author":"EM Rego","year":"2006","unstructured":"Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner RL et al. Leukamia with distinct phenotypes in transgenic mice expressing PML\/RAR alpha, PLZF\/RAR alpha or NPM\/RAR alpha. Oncogene 2006; 25: 1974\u20131979.","journal-title":"Oncogene"},{"key":"BFleu201239_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm.1891","volume":"14","author":"R Nasr","year":"2008","unstructured":"Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008; 14: 1333\u20131342.","journal-title":"Nat Med"},{"key":"BFleu201239_CR14","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1182\/blood-2011-02-329367","volume":"117","author":"J Ablain","year":"2011","unstructured":"Ablain J, de The H . Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011; 117: 5795\u20135802.","journal-title":"Blood"},{"key":"BFleu201239_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2008.12.012","volume":"15","author":"SC Kogan","year":"2009","unstructured":"Kogan SC . Curing APL: differentiation or destruction? Cancer Cell 2009; 15: 7\u20138.","journal-title":"Cancer Cell"},{"key":"BFleu201239_CR16","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V82.11.3241.3241","volume":"82","author":"P Fenaux","year":"1993","unstructured":"Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all transretinoic acid in newly diagnosed acute promyelicytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241\u20133249.","journal-title":"Blood"},{"key":"BFleu201239_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","volume":"337","author":"MS Tallman","year":"1997","unstructured":"Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021\u20131028.","journal-title":"N Engl J Med"},{"key":"BFleu201239_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/sj.leu.2404118","volume":"20","author":"RE Gallagher","year":"2006","unstructured":"Gallagher RE, Schachter-Tokarz EL, Zhou DC, Ding W, Kim SH, Sankoorikal BJ et al. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure. Leukemia 2006; 20: 556\u2013562.","journal-title":"Leukemia"},{"key":"BFleu201239_CR19","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969\u20136978.","journal-title":"EMBO J"},{"key":"BFleu201239_CR20","first-page":"2","volume":"61","author":"FF Ferrara","year":"2001","unstructured":"Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001; 61: 2\u20137.","journal-title":"Cancer Res"},{"key":"BFleu201239_CR21","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1172\/JCI200111537","volume":"108","author":"LZ He","year":"2001","unstructured":"He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321\u20131330.","journal-title":"J Clin Invest"},{"key":"BFleu201239_CR22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/jnci\/90.21.1621","volume":"90","author":"RP Warrell","year":"1998","unstructured":"Warrell RP, He L-Z, Richon V, Calleja E, Pandolfi PP . Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621\u20131625.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201239_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266\u20131269.","journal-title":"Blood"},{"key":"BFleu201239_CR24","first-page":"986","volume":"90","author":"E Raffoux","year":"2005","unstructured":"Raffoux E, Chaibi P, Dombret H, Degos L . Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 986\u2013988.","journal-title":"Haematologica"},{"key":"BFleu201239_CR25","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1158\/1078-0432.CCR-08-2786","volume":"15","author":"M Bots","year":"2009","unstructured":"Bots M, Johnstone RW . Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15: 3970\u20133977.","journal-title":"Clin Cancer Res"},{"key":"BFleu201239_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.01.005","volume":"7","author":"J Zhu","year":"2005","unstructured":"Zhu J, Zhou J, Peres L, Riaucoux F, Honor\u00e9 N, Kogan S et al. A sumoylation site in PML\/RARA is essential for leukemic transformation. Cancer Cell 2005; 7: 143\u2013153.","journal-title":"Cancer Cell"},{"key":"BFleu201239_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1073\/pnas.91.3.1178","volume":"91","author":"Z Chen","year":"1994","unstructured":"Chen Z, Guidez F, Rousselot P, Agadir A, Chen SJ, Wang ZY et al. PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci USA 1994; 91: 1178\u20131182.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201239_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1128\/MCB.18.1.122","volume":"18","author":"RK Slany","year":"1998","unstructured":"Slany RK, Lavau C, Clearly ML . The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122\u2013129.","journal-title":"Mol Cell Biol"},{"key":"BFleu201239_CR29","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/blood.V94.2.793","volume":"94","author":"C Du","year":"1999","unstructured":"Du C, Redner RL, Cooke MP, Lavau C . Overexpression of wild-type retinoic acid receptor alpha (RAR alpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RAR alpha-fusion genes. Blood 1999; 94: 793\u2013802.","journal-title":"Blood"},{"key":"BFleu201239_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2007.06.004","volume":"12","author":"J Zhu","year":"2007","unstructured":"Zhu J, Nasr R, Peres L, Riaucoux-Lormi\u00e8re F, Honor\u00e9 N, Berthier C et al. RXR is an essential component of the oncogenic PML\/RARA complex in vivo. Cancer Cell 2007; 12: 23\u201335.","journal-title":"Cancer Cell"},{"key":"BFleu201239_CR31","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1073\/pnas.94.6.2551","volume":"94","author":"D Brown","year":"1997","unstructured":"Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG et al. A PML RAR alpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 2551\u20132556.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201239_CR32","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2002-12-3779","volume":"102","author":"P Westervelt","year":"2003","unstructured":"Westervelt P, Lane AA, Pollock JL, Oldfather K, Holt MS, Zimonjic DB et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 2003; 102: 1857\u20131865.","journal-title":"Blood"},{"key":"BFleu201239_CR33","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1182\/blood-2001-11-0089","volume":"100","author":"S Minucci","year":"2002","unstructured":"Minucci S, Monestiroli S, Giavara S, Ronzoni S, Marchesi F, Insinga A et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 2002; 100: 2989\u20132995.","journal-title":"Blood"},{"key":"BFleu201239_CR34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.189.7.1043","volume":"189","author":"V Lallemand-Breitenbach","year":"1999","unstructured":"Lallemand-Breitenbach V, Guillemin M-C, Janin A, Daniel MT, Degos L, Kogan SC et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999; 189: 1043\u20131052.","journal-title":"J Exp Med"},{"key":"BFleu201239_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/89050","volume":"7","author":"L Altucci","year":"2001","unstructured":"Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H . Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680\u2013686.","journal-title":"Nat Med"},{"key":"BFleu201239_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.4161\/cc.4.6.1717","volume":"4","author":"A Insinga","year":"2005","unstructured":"Insinga A, Minucci S, Pelicci PG . Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 2005; 4: 741\u2013743.","journal-title":"Cell Cycle"},{"key":"BFleu201239_CR37","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1182\/blood-2008-10-182071","volume":"114","author":"FC Guibal","year":"2009","unstructured":"Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A et al. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood 2009; 114: 5415\u20135425.","journal-title":"Blood"},{"key":"BFleu201239_CR38","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/leu.2009.63","volume":"23","author":"S Wojiski","year":"2009","unstructured":"Wojiski S, Guibal FC, Kindler T, Lee BH, Jesneck JL, Fabian A et al. PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia 2009; 23: 1462\u20131471.","journal-title":"Leukemia"},{"key":"BFleu201239_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1158\/2159-8290.CD-11-0087","volume":"1","author":"J Ablain","year":"2011","unstructured":"Ablain J, Nasr R, Bazarbachi A, de The H . Oncoprotein proteolysis, an unexpected Achille's Heel of cancer cells? Cancer Discovery 2011; 1: 117\u2013127.","journal-title":"Cancer Discovery"},{"key":"BFleu201239_CR40","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","volume":"65","author":"G Bug","year":"2005","unstructured":"Bug G, Gul H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005; 65: 2537\u20132541.","journal-title":"Cancer Res"},{"key":"BFleu201239_CR41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1158\/0008-5472.CAN-04-3063","volume":"65","author":"L De Felice","year":"2005","unstructured":"De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005; 65: 1505\u20131513.","journal-title":"Cancer Res"},{"key":"BFleu201239_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.leukres.2010.06.024","volume":"35","author":"K Schwarz","year":"2011","unstructured":"Schwarz K, Romanski A, Puccetti E, Wietbrauk S, Vogel A, Keller M et al. The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells. Leuk Res 2011; 35: 119\u2013125.","journal-title":"Leuk Res"},{"key":"BFleu201239_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3324\/haematol.10758","volume":"92","author":"G Bug","year":"2007","unstructured":"Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007; 92: 542\u2013545.","journal-title":"Haematologica"},{"key":"BFleu201239_CR44","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrc1719","volume":"5","author":"V Lallemand-Breitenbach","year":"2005","unstructured":"Lallemand-Breitenbach V, Zhu J, Kogan S, Chen Z, de The H . Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia. Nat Rev Cancer 2005; 5: 821\u2013827.","journal-title":"Nat Rev Cancer"},{"key":"BFleu201239_CR45","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.V95.5.1541.005k28_1541_1550","volume":"95","author":"SC Kogan","year":"2000","unstructured":"Kogan SC, Hong SH, Shultz DB, Privalsky ML, Bishop JM . Leukemia initiated by PMLRARalpha: the PML domain plays a critical role while retinoic acid-mediated transactivation is dispensable. Blood 2000; 95: 1541\u20131550.","journal-title":"Blood"},{"key":"BFleu201239_CR46","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1084\/jem.20050616","volume":"203","author":"H Matsushita","year":"2006","unstructured":"Matsushita H, Scaglioni PP, Bhaumik M, Rego EM, Cai LF, Majid SM et al. In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemia. J Exp Med 2006; 203: 821\u2013828.","journal-title":"J Exp Med"},{"key":"BFleu201239_CR47","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1128\/MCB.21.7.2259-2268.2001","volume":"21","author":"WS Wu","year":"2001","unstructured":"Wu WS, Vallian S, Seto E, Yang WM, Edmondson D, Roth S et al. The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 2001; 21: 2259\u20132268.","journal-title":"Mol Cell Biol"},{"key":"BFleu201239_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35018127","volume":"406","author":"M Pearson","year":"2000","unstructured":"Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207\u2013210.","journal-title":"Nature"},{"key":"BFleu201239_CR49","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.emboj.7600109","volume":"23","author":"A Insinga","year":"2004","unstructured":"Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 2004; 23: 1144\u20131154.","journal-title":"EMBO J"},{"key":"BFleu201239_CR50","first-page":"111","volume":"39","author":"WS Fortson","year":"2011","unstructured":"Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011; 39: 111\u2013119.","journal-title":"Int J Oncol"},{"key":"BFleu201239_CR51","first-page":"787","volume":"37","author":"T Kawano","year":"2010","unstructured":"Kawano T, Akiyama M, Agawa-Ohta M, Mikami-Terao Y, Iwase S, Yanagisawa T et al. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation. Int J Oncol 2010; 37: 787\u2013795.","journal-title":"Int J Oncol"},{"key":"BFleu201239_CR52","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2002-02-0614","volume":"100","author":"S Cote","year":"2002","unstructured":"Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C et al. Response to histone deacetylase inhibition of novel PML\/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 2002; 100: 2586\u20132596.","journal-title":"Blood"},{"key":"BFleu201239_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.phrs.2010.02.010","volume":"62","author":"C Mercurio","year":"2010","unstructured":"Mercurio C, Minucci S, Pelicci PG . Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010; 62: 18\u201334.","journal-title":"Pharmacol Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201239","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201239.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:14:19Z","timestamp":1648739659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["BFleu201239"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.39","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]},"assertion":[{"value":"17 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}